


Humana.


Prior Authorization Optimization

May 2019



Agenda

- 01 | Overview of existing landscape
- 02 | Why & how (current and planned initiatives)
- 03 | Da Vinci FHIR Prior Authorization Support
- 04 | Broader perspective
- 05 | Q&A





Humana Prior Authorization Overview



278 is our standard Response is 'real-time' regardless of submission mode

- ~ 35,000 278s per day ~ 80% automated approval
- ~ 70% real time electronic (B2B & portal)

Industry Overview


Administrative prior authorization processes have been estimated to contribute as much as \$25 billion annually¹ to the cost of healthcare and have been linked to negative effects on patient care and provider performance.

Although Humana has supported the real-time 278 standard for many years, this is not true across the industry. While electronic prior authorization emphasis has attempted to reduce burden, adoption across the industry continues to be low with only 12% use of form 278 in 2018. Industry barriers mentioned include lack of operating rules, ubiquity of payer web portals and a myriad of state laws, and some components of the workflow occur outside the scope of the electronic standard.

While electronic PA is progressive, it is not transformative. Payers have levers to reduce inefficient communications and increase data exchange efficiency with providers.

Opportunities Informed by Clinicians

Feature/Function






Current Initiatives Examples



- Da Vinci PAS (including CRD and DTR)
- EHR specific optimization
- Authorization Questionnaires
- Automation BOTs
- Analytics at point of submission
- NLP/OCR for medical necessity documentation
- FAX automation with NLP
- Watson Al for IVR

Da Vinci Prior Authorization Support



Improve transparency

Reduce effort for prior authorization

Leverage available clinical content and increase automation

CRD



DTR



Prior Authorization Response

✓ Massive skin edema (anasarca) with complications (eg, tissue breakdown with infection, inability to void due to edema)	☐ Pulmonary edema that is persistent as indicated by ALL of the following	☐ Tachypnea that persists despite emergency department and observation care treatment
□ Dyspnea (above baseline) that persists despite emergency department and observation care treatment	☐ Altered mental status that is severe or persistent	☐ Increased creatinine (new on laboratory test) with reduction of more than 50% in estimated glomerular filtration rate from baseline eGFR - Adult Calculator
☐ Progressively (ongoing) rising creatinine (known from past laboratory test) with reduction of more than 25% in estimated	☐ Acute renal failure	☐ Acute peripheral ischemia (eg, examination shows pulseless, cool, mottled, or cyanotic extremity)
glomerular filtration rate from baseline eGFR - Adult Calculator	☐ Pulmonary artery catheter monitoring needed	Other condition, treatment, or monitoring requiring inpatient admission
Submit	nomoning needed	

Broader Perspective

Many FHIR initiatives of which PA is one of the most critical FAST, Da Vinci, Argonaut, CARIN



FHIR provides mechanisms which compliment the X12 baseline Adjacent integrations such as coverage requirements discovery and documentation template and rules streamline the overall process (this may be a Humana bias given that we use 278)

Payer agnosticism is a key consideration

Payer rules may necessarily different but the workflow experience doesn't have to be

Thank you

Humana.



Humana_®